Literature DB >> 28625216

Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11.

J W Keeley1, W Gaebel2.   

Abstract

The subtype system for categorising presentations of schizophrenia will be removed from International Classification of Diseases 11th Revision. In its place will be a system for rating six domains of psychotic disorder pathology: positive symptoms, negative symptoms, depressive symptoms, manic symptoms, psychomotor symptoms and cognitive symptoms. This paper outlines the rationale and description of the proposed symptom rating scale, including current controversies. In particular, the scale could adopt either a 4-point severity rating or a 2-point presence/absence rating. The 4-point scale has the advantage of gathering more information, but potentially at the cost of reliability. The paper concludes by describing the field testing process for evaluating the proposed scale.

Entities:  

Keywords:  ICD-11; psychotic disorders; schizophrenia; subtype

Mesh:

Year:  2017        PMID: 28625216      PMCID: PMC6998858          DOI: 10.1017/S2045796017000270

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  22 in total

Review 1.  How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment.

Authors:  V Peralta; M J Cuesta
Journal:  Schizophr Res       Date:  2001-04-30       Impact factor: 4.939

Review 2.  Categorical vs dimensional classifications of psychotic disorders.

Authors:  Melissa Potuzak; Caitlin Ravichandran; Kathryn E Lewandowski; Dost Ongür; Bruce M Cohen
Journal:  Compr Psychiatry       Date:  2012-06-07       Impact factor: 3.735

3.  Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia.

Authors:  Taina Mattila; Maarten Koeter; Tamar Wohlfarth; Jitschak Storosum; Wim van den Brink; Lieuwe de Haan; Eske Derks; Hubertus Leufkens; Damiaan Denys
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

Review 5.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

Authors:  Michael F Green; Robert S Kern; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

6.  Gender differences in the frequency of schizophrenic subtypes in unselected hospitalized patients.

Authors:  S Beratis; J Gabriel; S Hoidas
Journal:  Schizophr Res       Date:  1997-02-28       Impact factor: 4.939

7.  Outcome and family study of the subtypes of schizophrenia in the west of Ireland.

Authors:  K S Kendler; M McGuire; A M Gruenberg; D Walsh
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

8.  Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11.

Authors:  David L Braff; James Ryan; Anthony J Rissling; William T Carpenter
Journal:  Schizophr Bull       Date:  2013-05-14       Impact factor: 9.306

Review 9.  Schizophrenia, "just the facts" 4. Clinical features and conceptualization.

Authors:  Rajiv Tandon; Henry A Nasrallah; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2009-03-27       Impact factor: 4.939

10.  Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia.

Authors:  W S Fenton; T H McGlashan
Journal:  Arch Gen Psychiatry       Date:  1991-11
View more
  3 in total

1.  ICD-11 chapter on mental and behavioural disorders: heralding new ways of seeing old problems.

Authors:  O Gureje
Journal:  Epidemiol Psychiatr Sci       Date:  2018-06       Impact factor: 6.892

2.  Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study.

Authors:  Mustafa Yildiz; Aysel Incedere; Mehmet Buğrahan Gürcan; Emre Osman
Journal:  Noro Psikiyatr Ars       Date:  2021-08-04       Impact factor: 1.339

Review 3.  Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.

Authors:  Nina Dedic; Heather Dworak; Courtney Zeni; Grazia Rutigliano; Oliver D Howes
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.